Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.
NCT04795661
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
240
Enrollment
OTHER
Sponsor class
Conditions
Localized Resectable Tumor
MSI/dMMR
Interventions
DRUG:
Pembrolizumab
Sponsor
Centre Leon Berard